[go: up one dir, main page]

GT200600240A - Anticuerpos monoclonales anti-trkb y usos de los mismos - Google Patents

Anticuerpos monoclonales anti-trkb y usos de los mismos

Info

Publication number
GT200600240A
GT200600240A GT200600240A GT200600240A GT200600240A GT 200600240 A GT200600240 A GT 200600240A GT 200600240 A GT200600240 A GT 200600240A GT 200600240 A GT200600240 A GT 200600240A GT 200600240 A GT200600240 A GT 200600240A
Authority
GT
Guatemala
Prior art keywords
same
monoclonal antibodies
antibodies
trkb monoclonal
trkb
Prior art date
Application number
GT200600240A
Other languages
English (en)
Inventor
Cho Seongeun
Gill Davinder Singh
Tan Xiang-Yang
Qian Ming Diana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200600240A publication Critical patent/GT200600240A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA ANTICUERPOS MONOCLONALES PARA EL TRKB HUMANO. EN ALGUNAS MODALIDADES LOS ANTICUERPOS DE LA INVENCIÓN UNEN Y ACTIVAN EL TRKB HUMANO. LAS COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS ANTICUERPOS SON PROPORCIONADOS COMO MÉTODOS PARA PREPARAR LOS ANTICUERPOS Y MÉTODOS PARA UTILIZAR LOS MISMOS CON PROPÓSITOS DE TRATAMIENTO, DETECCIÓN Y PURIFICACIÓN. T2006
GT200600240A 2005-06-06 2006-06-05 Anticuerpos monoclonales anti-trkb y usos de los mismos GT200600240A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68770505P 2005-06-06 2005-06-06

Publications (1)

Publication Number Publication Date
GT200600240A true GT200600240A (es) 2007-03-14

Family

ID=37400063

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600240A GT200600240A (es) 2005-06-06 2006-06-05 Anticuerpos monoclonales anti-trkb y usos de los mismos

Country Status (21)

Country Link
US (2) US7750122B2 (es)
EP (2) EP1891114A2 (es)
JP (1) JP2008545781A (es)
KR (1) KR20080032070A (es)
CN (1) CN101273064A (es)
AR (1) AR053401A1 (es)
AU (1) AU2006255101A1 (es)
BR (1) BRPI0610938A2 (es)
CA (1) CA2610771A1 (es)
EC (1) ECSP077978A (es)
GT (1) GT200600240A (es)
IL (1) IL187710A0 (es)
MX (1) MX2007015292A (es)
NI (1) NI200700315A (es)
NO (1) NO20076157L (es)
NZ (1) NZ563941A (es)
PA (1) PA8678401A1 (es)
PE (1) PE20070183A1 (es)
RU (1) RU2007144678A (es)
TW (1) TW200722437A (es)
WO (1) WO2006133164A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
GEP20094629B (en) 2003-03-19 2009-03-10 Biogen Idec Inc Nogo receptor binding protein
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
BRPI0613387A2 (pt) 2005-07-08 2011-01-11 Biogen Idec Inc anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
KR20140087058A (ko) 2005-11-30 2014-07-08 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
KR20090088896A (ko) * 2006-11-09 2009-08-20 아이알엠 엘엘씨 효현제 ｔｒｋｂ 항체 및 그의 용도
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2114436A1 (en) * 2006-12-20 2009-11-11 Rinat Neuroscience Corp. Trkb agonists for treating autoimmune disorders
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
EP2205071B1 (en) * 2007-10-11 2015-07-22 Biogen MA Inc. Lingo-1 antagonists and trkb agonists for use in the treatment of glaucoma
US20100297115A1 (en) * 2007-10-23 2010-11-25 Novartis Ag Use of trkb antibodies for the treatment of respiratory disorders
WO2009061500A1 (en) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
CA2729961C (en) 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Li113, li62 variant co2, anti-lingo antibodies
WO2010086828A2 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
AU2010243551B2 (en) * 2009-04-30 2015-03-26 Ablynx Nv Method for the production of domain antibodies
WO2011103667A1 (en) * 2010-02-26 2011-09-01 6452728 Canada Inc. Agonistic antibodies to trkb receptors and uses thereof
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
MX359070B (es) 2010-12-01 2018-09-13 Alderbio Holdings Llc Composiciones anti-ngf y uso de las mismas.
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
GB2491106A (en) 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
CN102645542A (zh) * 2012-04-20 2012-08-22 苏州大学 Bdnf酶联免疫测定试剂盒
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
CN102901815B (zh) * 2012-11-05 2014-10-22 武汉远征世纪制药有限公司 一种检测TrkB受体816/817位酪氨酸位点活性的ELISA试剂盒及其使用方法
HK1214830A1 (zh) 2012-11-05 2016-08-05 Foundation Medicine, Inc. 新型ntrk1融合分子及其应用
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
AU2014207342C1 (en) 2013-01-18 2019-04-04 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
JP6868394B2 (ja) 2014-05-16 2021-05-12 ファイザー・インク 二重特異性抗体
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
JP7039468B2 (ja) * 2015-11-17 2022-03-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 神経およびその他の障害の処置のための結合アゴニスト
JP2019517787A (ja) * 2016-05-03 2019-06-27 ザ スクリプス リサーチ インスティテュート 神経変性障害の処置のためのＴｒｋＢアゴニスト抗体
US12098202B2 (en) 2016-10-10 2024-09-24 The National Institute for Biotechnology in the Negev Ltd. Non-cytotoxic modified cells and use thereof
US9914781B1 (en) 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
EP3596126A4 (en) 2017-03-15 2021-03-03 Tsinghua University NOVEL ANTI-TRKB ANTIBODIES
US10793634B2 (en) * 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
MX2020003550A (es) 2017-11-30 2020-08-03 Regeneron Pharma Anticuerpos monoclonales anti-trkb y metodos de uso.
CN110028585A (zh) * 2019-02-18 2019-07-19 广东三九脑科医院 兔抗人trk蛋白单克隆抗体制备及其免疫组化用途
US20230000998A1 (en) 2019-11-22 2023-01-05 Ossianix, Inc. Bbb-shuttling-vnars conjugated to neurotrophic agonist antibodies to treat neurodegenerative diseases and conditions
WO2021155141A1 (en) * 2020-01-30 2021-08-05 Fred Hutchinson Cancer Research Center Antibody-based compositions for targeting tropomyosin receptor kinase b (trkb) isoforms
GB202004832D0 (en) * 2020-04-01 2020-05-13 Instituto De Medicina Molecular Faculdade De Medicina Univ De Lisboa Therapeutic agaents, pharmaceutical compositions, and associated biomarkers
WO2023125485A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited TrkB ANTIBODY AND APPLICATION THEREOF

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5817471A (en) 1991-03-14 1998-10-06 The United States Of America As Represented By The Department Of Health And Human Services Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
US5231001A (en) 1991-03-14 1993-07-27 The United States Of America As Represented By The Department Of Health And Human Services Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
ZA922947B (en) 1991-04-23 1993-01-27 Regeneron Pharma Assay systems for neurotrophin activity
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5625121A (en) 1993-09-02 1997-04-29 Bristol-Myers Squibb Company Mice deficient in nerve growth factor receptors encoded by trkB
US5753225A (en) 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US20040058416A1 (en) 1994-03-18 2004-03-25 Presta Leonard G. Human trk receptors and neurotrophic factor inhibitors
US5601820A (en) 1994-07-07 1997-02-11 Children's Hospital Of Philadelphia Compositions and methods of making and using human full length TRK-B
US5770577A (en) 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5688911A (en) 1995-05-03 1997-11-18 Schneider; Rainer Trk neurotrophin binding motifs
US5880153A (en) 1995-11-13 1999-03-09 Spinal Cord Society Method for upregulation of TRKB and TRKC receptors in central nervous system neurons
JPH10212241A (ja) 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
WO1998003546A1 (en) 1996-07-19 1998-01-29 Amgen Inc. Analogs of cationic proteins
US6800607B2 (en) 2000-02-29 2004-10-05 Ltt Bio-Pharma Co., Ltd. Modified BDNF
AU2001271422B2 (en) 2000-06-22 2005-12-22 Genentech, Inc. Agonist anti-trk-C monoclonal antibodies
US7060429B2 (en) 2001-02-22 2006-06-13 University Of Maryland, Baltimore Treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms
US20020169154A1 (en) 2001-04-04 2002-11-14 Cephalon, Inc. Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents
US20060148749A1 (en) 2002-02-22 2006-07-06 University Of Maryland Novel treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms
US20040186044A1 (en) 2002-11-06 2004-09-23 Cosgaya Jose Miguel Modulation of myelination by interaction with P75 and TRK receptors

Also Published As

Publication number Publication date
IL187710A0 (en) 2008-08-07
NO20076157L (no) 2008-02-07
US20070059304A1 (en) 2007-03-15
AU2006255101A1 (en) 2006-12-14
EP1891114A2 (en) 2008-02-27
KR20080032070A (ko) 2008-04-14
US20110150893A1 (en) 2011-06-23
PA8678401A1 (es) 2009-05-15
WO2006133164A2 (en) 2006-12-14
US7750122B2 (en) 2010-07-06
EP2298813A3 (en) 2012-03-21
ECSP077978A (es) 2008-01-23
TW200722437A (en) 2007-06-16
NI200700315A (es) 2008-07-03
WO2006133164A3 (en) 2007-03-15
EP2298813A2 (en) 2011-03-23
RU2007144678A (ru) 2009-07-20
CA2610771A1 (en) 2006-12-14
JP2008545781A (ja) 2008-12-18
PE20070183A1 (es) 2007-02-26
BRPI0610938A2 (pt) 2010-08-03
MX2007015292A (es) 2008-02-21
CN101273064A (zh) 2008-09-24
AR053401A1 (es) 2007-05-02
NZ563941A (en) 2011-09-30

Similar Documents

Publication Publication Date Title
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
UY32812A (es) Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana.
CR11795A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
ECSP088508A (es) Antagonistas de neuropilina
CR20130134A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CR20120449A (es) Formas de rifaximina y sus usos
GT200500260A (es) Amidas biciclicas como inhibidores de cinasa.
ECSP13012402A (es) Inmunoglobulinas con dominio variable dual y su uso
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
ECSP13012648A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
ECSP12011922A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
DOP2012000104A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
UY33707A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CR20130058A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CR20120267A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
ECSP12012244A (es) Pirrolobenzodiacepinas y conjugados de las mismas
UY33492A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
MX379228B (es) Compuestos y usos de estos para la modulación de la hemoglobina.
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
GT201300058A (es) Composiciones de anticuerpos anti-vegfr-3
ECSP13012523A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CL2011000045A1 (es) Compuestos derivados de cinolin-4-(1h)-ona; procedimiento de preparacion; composicion farmaceutica; utiles en el tratamiento de enfermedades inflamatorias, autoinmunes, alergicas, infecciosas, neurodegenerativas, entre otras.
AR115423A2 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana
UY33631A (es) Anticuerpos anti-cd48 y usos de los mismos
CO6541599A2 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas